Clinical trial
Flavopiridol in Treating Patients With Metastatic Malignant Melanoma
NCT00005971 · NCIC Clinical Trials Group, Other · Completed
Key facts
| NCT number | NCT00005971 |
|---|---|
| Title | Flavopiridol in Treating Patients With Metastatic Malignant Melanoma |
| Official title | A Phase II Study of Flavopiridol (HMR 1275; NSC 649890) in Patients With Previously Untreated Metastatic Malignant Melanoma |
| Lead sponsor | NCIC Clinical Trials Group, Other |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Melanoma (Skin) |
| Intervention type | Drug |
| Interventions | alvocidib |
| Enrollment | 17 |
| Start date | Jul 4, 2000 |
| Primary completion | Aug 24, 2001 |
| Completion | Dec 21, 2009 |
| First posted | May 21, 2003 |
| Last update posted | Apr 9, 2020 |
| Countries | Canada |
At a glance
- 10–99 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: